Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.91 USD | +0.34% | -2.07% | -13.88% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 407
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Collaboration
99.7
%
| 0 | 36.4 % | 370 | 99.7 % | +84,762.39% |
Grant
0.3
%
| 1 | 63.6 % | 1 | 0.3 % | +58.27% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Switzerland and United States
100.0
%
| 1 | 100.0 % | 371 | 100.0 % | +30,885.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 45 | 15-07-31 |
Raju Prasad
DFI | Director of Finance/CFO | 40 | 23-03-13 |
Stephen Kennedy
CTO | Chief Tech/Sci/R&D Officer | 67 | 19-09-30 |
Jonathan Terrett
CTO | Chief Tech/Sci/R&D Officer | - | 17-02-27 |
Susan Kim
IRC | Investor Relations Contact | - | - |
Alex Harding
PRN | Corporate Officer/Principal | - | 23-01-04 |
Human Resources Officer | - | 16-07-31 | |
Jim Kasinger
LAW | General Counsel | 52 | 17-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Doug Treco Treco
BRD | Director/Board Member | 66 | 20-06-10 |
Simeon George
BRD | Director/Board Member | 46 | 15-04-28 |
Ali Behbahani
BRD | Director/Board Member | 47 | 15-03-31 |
Maria Fardis
BRD | Director/Board Member | 56 | 22-06-08 |
Katherine High
BRD | Director/Board Member | 72 | 19-06-10 |
John Greene
BRD | Director/Board Member | 58 | 19-06-10 |
Samarth Kulkarni
CEO | Chief Executive Officer | 45 | 15-07-31 |
Director/Board Member | 61 | 21-06-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 85,053,407 | 83,305,141 ( 97.94 %) | 170,316 ( 0.2002 %) | 97.94 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.88% | 4.56B | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- CRSP Stock
- Company CRISPR Therapeutics AG